Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02894112 · ClinicalTrials.gov registry record · NA
Effects of Fluid Milk in Attenuating Hyperglycemia and Hypertriglyceridemia After Meal
A NA study, sponsored by University of Texas at Austin.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT02894112: Completed NA study, sponsored by University of Texas at Austin.
NCT02894112 is a NA study that has completed, run by University of Texas at Austin. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02894112, a NA study, has completed, sponsored by University of Texas at Austin.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
Epidemiological studies indicate that risk of type 2 diabetes is lower when milk is consumed in the regular diet. Milk products are unique in that they produce high insulin response despite their low glycemic index. The general aim of the proposed study is to determine the effect of fluid milk on attenuating the postprandial surge in plasma glucose and triglyceride after meals and its associated physiological mechanisms. The investigators hypothesize that the consumption of one or two servings of non-fat milk added to a standard oral glucose tolerance test (OGTT) solution or the high fat tolerance test meal will attenuate postprandial hyperglycemia and triglyceridemia. The investigators hypothesize that the postulated improvement in postprandial metabolic response due to the consumption of fluid milk will be associated with increased postprandial insulin secretion as well as insulin-mediated endothelial vasodilation and whole-limb perfusion.
Interventions
- DIETARY_SUPPLEMENT non-fat milk
- DIETARY_SUPPLEMENT carbohydrate control beverage
- DIETARY_SUPPLEMENT caloric control beverage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-12 |
| Phase | NA |
What the finished NCT02894112 record still lists
NCT02894112 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which non-fat milk is the first listed.
NCT02894112 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02894112 about?
NCT02894112 is a clinical study titled "Effects of Fluid Milk in Attenuating Hyperglycemia and Hypertriglyceridemia After Meal". Epidemiological studies indicate that risk of type 2 diabetes is lower when milk is consumed in the regular diet. Milk products are unique in that they produce high insulin response despite their low glycemic index. The general aim of the proposed study is to determine the effect of fluid milk on at...
What is the current status of trial NCT02894112?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2013-04. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02894112?
The interventions under investigation include: non-fat milk (DIETARY_SUPPLEMENT), carbohydrate control beverage (DIETARY_SUPPLEMENT), caloric control beverage (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02894112?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02894112's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia